How to buy Lyell Immunopharma stock (Lyell Immunopharma)

Lyell Immunopharma is a biotechnology business based in the US. Lyell Immunopharma shares (LYEL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.61 – a decrease of 4.38% over the previous week. Lyell Immunopharma employs 224 staff and has a trailing 12-month revenue of around $63,000.

Our top picks for where to buy Lyell Immunopharma stock

Buy Lyell Immunopharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lyell Immunopharma stock price (NASDAQ: LYEL)

Use our graph to track the performance of LYEL stocks over time.

Lyell Immunopharma shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.61
52-week range	$0.59 - $3.26
50-day moving average more info button	$1.03
200-day moving average more info button	$1.71
Wall St. target price	$2.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.79

Is it a good time to buy Lyell Immunopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lyell Immunopharma price performance over time

Historical closes compared with the close of $0.6129 from 2024-12-24

1 week (2024-12-19)	-4.38%
1 month (2024-11-26)	-33.65%
3 months (2024-09-26)	-59.68%
6 months (2024-06-26)	-53.03%

1 year (2023-12-26)	-71.23%
2 years (2022-12-23)	-79.90%
3 years (2021-12-23)	8.21
5 years (2019-12-22)	N/A

Lyell Immunopharma financials

Revenue TTM	$63,000
Gross profit TTM	$84.7 million
Return on assets TTM	-19.12%
Return on equity TTM	-33.22%
Profit margin	0%
Book value	$2.07
Market Capitalization more info button	$173.8 million

TTM: trailing 12 months

Lyell Immunopharma share dividends

We're not expecting Lyell Immunopharma to pay a dividend over the next 12 months.

You may also wish to consider:

Lyell Immunopharma share price volatility

Over the last 12 months, Lyell Immunopharma's shares have ranged in value from as little as $0.5949 up to $3.2556. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lyell Immunopharma's is -0.483. This would suggest that Lyell Immunopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Lyell Immunopharma has bucked the trend.

To put Lyell Immunopharma's beta into context you can compare it against those of similar companies.

• Agios Pharm (AGIO.US): 0.751
• Athenex (ATNX.US): 1.3452
• Clovis Oncology (CLVS.US): 0.2205

Lyell Immunopharma overview

Lyell Immunopharma, Inc. , a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Frequently asked questions

What percentage of Lyell Immunopharma is owned by insiders or institutions?
Currently 13.438% of Lyell Immunopharma shares are held by insiders and 59.777% by institutions. How many people work for Lyell Immunopharma?
Latest data suggests 224 work at Lyell Immunopharma. When does the fiscal year end for Lyell Immunopharma?
Lyell Immunopharma's fiscal year ends in December. Where is Lyell Immunopharma based?
Lyell Immunopharma's address is: 201 Haskins Way, South San Francisco, CA, United States, 94080 What is Lyell Immunopharma's ISIN number?
Lyell Immunopharma's international securities identification number is: US55083R1041